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Synthesis of Dimeric Analogs of Adenophostin A that Potently Evoke 
Ca2+ Release through IP3 Receptors 
Amol M. Vibhute,a Poornenth Pushpanandan,a Maria Varghese,a Vera Koniecnzy,b Colin 
W. Taylorb and Kana M. Sureshana* 
Inositol 1,4,5-trisphosphate receptors (IP3Rs) are tetrameric intracellular channels through which many extracellular 
stimuli initiate the Ca2+ signals that regulate diverse cellular responses. There is considerable interest in developing novel 
ligands of IP3R. Adenophostin A (AdA) is a potent agonist of IP3R and since some dimeric analogs of IP3R ligands are more 
potent than the corresponding monomer, we considered whether dimeric AdA analogs might provide agonists with 
increased potency. We previously synthesized  traizolophostin, in which a simple triazole replaced the adenine of AdA, and 
showed it be equipotent with AdA. Here, we used click chemistry to synthesize four homodimeric analogs of 
triazolophostin, connected by oligoethylene glycol chains of different length. We evaluated the potency of these analogs 
to release Ca2+ through type 1 IP3R and established that the newly synthesized dimers are equipotent to AdA or 
triazolophostin. 
Introduction 
Inositol 1,4,5-trisphosphate (IP3, 1, Fig 1) is an important 
second messenger that evokes Ca
2+
 release from intracellular 
stores through its interaction with IP3 receptors (IP3R) in the 
endoplasmic reticulum.
1
 IP3R are large tetrameric proteins, 
within which IP3 binding to each of the four subunits is 
required to initiate opening of the Ca
2+
-permeable channel.
2
 
High-resolution structures of the IP3-binding core (IBC, 
residues 224-604) have defined the interactions of IP3 with the 
IP3R.
3
 More recently, structures of the N-terminal region 
(residues 1-604)
4
 alongside a structure of the complete IP3R 
derived from cryo-electron microscopy have begun to suggest 
how IP3 binding might trigger opening of the intrinsic pore of 
the IP3R.
5
  
There is continuing interest in the development of potent 
agonists and antagonists of IP3R.
6
 The fungal metabolite, 
adenophostin A (AdA, 2, Fig. 1), binds to IP3R with greater 
affinity than IP3 and it is more potent than IP3 in evoking Ca
2+
 
release.
7
 AdA analogs with a nucleobase or base-surrogate are 
also more potent than IP3.
8
 Molecular docking
8j,m,9
 and 
mutation studies
10
 suggest that a cation-π interaction between 
the adenine moiety of AdA and Arg504 within the IBC 
contributes to the increased affinity of AdA. We recently 
reported synthesis of a library of active AdA analogs, 
triazolophostins, by using a click chemistry approach.11
 
These 
potent analogs have substituted triazoles as adenine 
surrogates. The simplest analog, triazolophostin (3, Fig. 1) was 
equipotent with AdA. 
Multimeric ligands often have greater affinity than 
monomeric ligands.
12
 This can be due to simultaneous binding 
to more than one binding site or a statistical effect arising from 
the local increase in ligand concentration.
13
 The former is 
unlikely for IP3R because the orientation of the IP3-binding 
sites within the tetrameric IP3R is unlikely to allow 
simultaneous binding of two ligands linked by a short 
tether.
4b,14
  
 
Fig. 1 The structures of IP3 (1), adenophostin A (2) and triazolophostin (3). 
A few multimeric ligands of IP3R have been reported. 
Before the location of the IP3-binding sites within IP3R was 
known, clustered bi- and tetra-dentate analogs of ribophostin 
(4, Fig. 2A) were synthesized, anticipating that if the spacing 
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between the linked ligands was appropriate they might bind 
simultaneously to the four IP3-binding sites.
15
 However, the 
potencies of the monomeric and polymeric ligands were rather 
similar. Several homodimeric
16
 and heterodimeric
17
 ligands of 
IP3 (5-10, Fig. 2B), particularly those with short linkers, were 
shown to bind to IP3R with increased affinity.
13d
 Very recently, 
dimers of 2-O-Bt-IP4/IP5 (11, Fig. 2C) were shown to be 
antagonists of IP3Rs.
18
 These results demonstrate that dimeric 
IP3R ligands can provide useful tools, some of which have 
greater affinity than the monomeric ligands. We therefore 
considered whether dimers of AdA might be more potent than 
AdA. 
 
Fig. 2 The representative structures of (A) ribophostin dimer 4, (B) homo and hetero 
dimers of IP3 (5-10) and (C) dimers of 2-Bt-IP4/IP5 11.    
Results and discussion 
As the synthesis of AdA dimers is challenging, we decided to 
make oligoethylene glycol-tethered dimers of triazolophostin 
(Fig. 3). We envisaged that use of click reaction
19
 with a linker 
connected to alkyne at both termini would ensure both 
formation of triazole and link the two monomers in one step. 
Previous studies suggested that short linkers were most likely 
to improve the affinity of homodimers.
13d 
We therefore 
selected spacers smaller than hexaethylene glycol. The linkers 
14a-d were synthesized by slightly modifying previously 
reported procedures.
20
 The oligoethylene glycols were first co-
evaporated with toluene and then treated with sodium 
hydride in the presence of excess propargyl bromide to get 
dipropargyl polyethylene glycols 14a-d in good to excellent 
yields. The azide 13 was synthesized from glucose and xylose 
by several protection-deprotection reactions followed by 
phosphorylation as reported earlier.
11 
The azide 13 was then 
treated with dialkynyl polyethylene glycols 14a-d in the 
presence of Cu(I) catalyst to get fully protected triazolophostin  
  
Fig. 3 The structure of dimeric analogs of triazolophostin 12.    
 
 
Scheme 1 Synthesis of triazolophostin dimers. Reagents and conditions: (a) ref 11; (b) 
Cu, CuSO4, H2O:
t
BuOH (1:1, v/v), rt, 24 h; (c) Pd(OH)2/C, cyclohexene, MeOH:H2O (10:1, 
v/v), 80 
o
C. 4 h; a, n = 2; b, n = 3; c, n = 4; d, n = 6.  
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dimers 15a-d in good yields. The debenzylation of protected 
triazolophostin dimers 15a-d was carried out using transfer 
hydrogenolysis in the presence of palladium and cyclohexene 
under reflux condition and the products were purified by ion-
exchange chromatography to yield dimers 12a-d, in excellent 
yields (Scheme 1). 
The dimeric ligands 12a-d were screened for their abilities 
to evoke Ca
2+
 release through IP3R (Table 1, Fig. 4). All four 
dimers were full agonists of IP3R, more potent than IP3, but 
similar in their potency to AdA and the monomer, 
triazolophostin. The similar potencies of 12a-d irrespective of 
their tether length suggest that these ligands might be 
interacting with IP3R1 in monodentate fashion. 
Table 1 Responses of IP3R1 to IP3 (1), monomer (3) and its dimeric analogs 12a-d.
a  
Ligand pEC50 EC50 
(nM) 
EC50 
w.r.t. 1b 
max. 
response 
(%) 
nH 
IP3 (1) 6.72 ± 0.12  190.5 1 69 ± 3  1.40 ± 0.16  
Monomer 
(3) 
7.86 ± 0.17 13.8 13.8 65 ± 1  1.66 ± 0.21 
12a 7.83 ± 0.18 14.8 12.9 68 ± 2  1.33 ± 0.12 
12b 7.85 ± 0.13 14.1 13.5 66 ± 1  1.89 ± 0.13 
12c 7.62 ± 0.11  24.0 7.9 61 ± 3 1.60 ± 0.16  
12d 7.84 ± 0.12  14.4 13.2 60 ± 1 1.94 ± 0.47  
aMaximal Ca2+ release, the half-maximally effective ligand concentration (EC50),      
-logEC50 (pEC50) and Hill coefficient (nH) are shown as means ± SEM (n = 3). 
bThe 
EC50 value of each ligand is also shown relative to that for IP3 (1) (    
      
      
). 
 
 
Fig. 4 Summary of Ca2+ release from permeabilized DT40-IP3R1 cells evoked by IP3, 
monomer 3 and its dimeric analogs 12a-d.  
Conclusions 
In conclusion, based on several previous reports that dimeric 
IP3R ligands can be more potent than the corresponding 
monomers, we anticipated that dimers of AdA might have 
increased potency. We used click chemistry to synthesize 
dimers of a potent analog of AdA (triazolophostin) linked by 
spacers of different length. In assays of Ca
2+
 release through 
IP3R, the dimeric ligands were no more potent than   the 
corresponding monomer (3). This suggests that whereas 
dimeric derivatives of IP3 have reduced efficacy but improved 
affinity,
10,21
 dimerization of AdA analogs does not improve 
their affinity.  
Experimental Section 
1. General methods 
The chemicals were purchased from commercial sources and 
used as received. The TLC plates were visualized under UV light 
and by dipping plates into either phosphomolybdic acid in 
MeOH or sulphuric acid in ethanol, followed by heating. All 
NMR experiments were carried out on a 500 MHz NMR 
spectrometer and at room temperature. Tetramethylsilane 
(TMS, δ 0.0 ppm) or the solvent reference (CDCl3, δ 7.26 ppm; 
D2O, δ 4.79 ppm) relative to TMS were used as the internal 
standard. The data are reported as follows: chemical shift in 
ppm (δ) (multiplicity [singlet (s), doublet (d), doublet of 
doublet (dd), triplet (t), quartet (q), and multiplet (m)], 
coupling constants [Hz], integration and peak identification). 
All NMR signals were assigned on the basis of 
1
H NMR, 
13
C 
NMR, COSY and HMQC experiments. 
13
C NMR spectra were 
recorded with complete proton decoupling. Carbon chemical 
shifts are reported in ppm (δ) relative to TMS with the 
respective solvent resonance as the internal standard. The 
concentration of the compounds for 
1
H NMR was 5 mg per 0.5 
mL and for 
13
C NMR it was 20 mg per 0.5 mL for protected 
compounds and 5-7 mg per 0.5 mL for final compounds in case 
of 
1
H and 
13
C NMR. Modified Brigg’s phosphate assay
22
 was 
employed to quantify each triazolophostin 12a-d. Silica gel 
230-400 mesh was used to perform flash column 
chromatography. 
2. General procedure for syntheses of fully protected 
triazolophostin dimers: 
To a solution of azide 13 (0.144 mmol) and dialkynyl PEG 14a-d 
(0.072) in H2O/
t
BuOH (1/1, v/v, 2 mL) was added Cu (0.036 g, 
0.57 mmol) and CuSO4 (8 mg, 0.028 mmol) and stirred at room 
temperature for 24 h. The reaction was monitored by TLC. 
When the TLC showed complete disappearance of the azide 
13, the mixture was filtered through a Celite bed and was 
partitioned between ethyl acetate and water. The organic 
layer was washed with brine. The organic layer was dried over 
anhyd. sodium sulphate, filtered and concentrated under 
reduced pressure. The residue thus obtained was purified by 
flash column chromatography using a mixture of acetone, 
diethyl ether and petroleum ether (4:2:15 v/v/v) as eluent to 
get pure 15a-d as a colourless gum. 
a. Protected triazolophostin dimer 15a: 
Click reaction of azide 13 (0.2 g, 0.144 mmol) with diyne 14a 
(0.011 g, 0.072 mmol) gave the protected dimer 15a (0.18 g, 
85%) as a colourless gum. 
1
H NMR (500 MHz, CDCl3) δ: 3.47-
3.57 (m, 18H, H-2′′, H-4′′, H-6′′A, and DEG-H), 3.73-3.75 (m, 2H, 
H-5′′), 4.20-4.23 (m, 2H, PhCH2), 4.27-4.32 (m, 8H, H-5′A and 
PhCH2), 4.30-4.45 (m, 10H, H-3′, H-4′, H-5′B, H-6′′B and PhCH2), 
4.57-4.59 (m, 2H, PhCH2), 4.63-4.66 (m, 4H, PhCH2), 4.68-4.73 
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(m, 6H, PhCH2), 4.80-4.93 (m, 16H, H-3′′, H-4′′ and PhCH2), 5.11 
(d, 2H, J = 3.2 Hz, H-1′′), 5.26-5.28 (m, 2H, H-2′) 6.24 (d, 2H, J = 
5.0 Hz, H-1′), 7.00 (d, 4H, J = 7.0 Hz, Ar-H), 7.05-7.19 (m, 82H, 
Ar-H), 7.26 (d, 4H, J = 7.0 Hz, Ar-H), 7.60 (s, 2H, H-5); 
13
C NMR 
(125 MHz, CDCl3) δ: 64.2, 68.3, 69.1, 69.2, 69.3, 69.5, 69.6, 
69.7, 69.9, 70.1, 70.4, 71.9, 73.3, 73.5, 74.1, 78.0, 78.5, 82.8, 
90.1, 95.7, 121.6, 127.6, 127.7, 127.9, 128.0, 128.1, 128.3, 
128.4, 128.5, 135.2, 135.7, 135.8, 136.1, 137.3, 137.5, 138.0, 
145.2; 
31
P NMR (202.4 MHz, CDCl3) δ: -1.484, -1.928, -2.146; 
HRMS (ESI) mass calcd for C158H166N6O39P6 [M]
+
 2956.9616, 
found 2956.9620. 
b. Protected triazolophostin dimer 15b: 
Click reaction of azide 13 (0.2 g, 0.144 mmol) with diyne 14b 
(0.016 g, 0.072 mmol) gave the protected dimer 15b (0.185 g, 
86%) as a colourless gum. 
1
H NMR (500 MHz, CDCl3) δ: 3.44-
3.57 (m, 22H, H-2′′, H-4′′, H-6′′A, and TEG-H), 3.75 (bs, 2H, H-
5′′), 4.21-4.30 (m, 10H, H-5′A and PhCH2), 4.42-4.43 (m, 10H, H-
3′, H-4′, H-5′B, H-6′′B and PhCH2), 4.57-4.59 (m, 2H, PhCH2), 
4.64-4.66 (m, 6H, PhCH2), 4.68-4.73 (m, 4H, PhCH2), 4.84-4.92 
(m, 16H, H-3′′, H-4′′ and PhCH2), 5.11 (bs, 2H, H-1′′), 5.27(bs, 
2H, H-2′) 6.24 (d, 2H, J = 5.0 Hz, H-1′), 7.00-7.25 (m, 90H, Ar-H), 
7.61 (s, 2H, H-5); 
13
C NMR (125 MHz, CDCl3) δ: 63.2, 67.3, 68.0, 
68.3, 68.4, 68.6, 68.7, 69.1, 69.4, 70.9, 72.3, 75.7, 75.8, 75.9, 
76.9, 77.5, 81.7, 89.0, 94.7, 120.6, 126.7, 127.0, 127.2, 127.4, 
134.2, 134.6, 135.1, 136.3, 136.5, 137.0, 144.2; 
31
P NMR (202.4 
MHz, CDCl3) δ: -1.486, -1.935, -2.155; HRMS (ESI) mass calcd 
for C160H170N6O40P6 [M]
+
 3000.9879, found 3000.9877. 
c. Protected triazolophostin dimer 15c: 
The reaction of azide 13 (0.2 g, 0.144 mmol) with diyne 14c 
(0.019 g, 0.072 mmol) gave the protected dimer 15c (0.175 g, 
81%) as a colourless gum. 
1
H NMR (500 MHz, CDCl3) δ: 3.54-
3.67 (m, 26H, H-2′′, H-4′′, H-6A′′, and TetraEG-H), 3.84 (bs, 2H, 
H-5′′), 4.30-4.32 (m, 2H, PhCH2), 4.37-4.39 (m, 8H, H-5′A and 
PhCH2), 4.48-4.53 (m, 10H, H-3′, H-4′, H-5′B, H-6′′B and PhCH2), 
4.66-4.68 (m, 2H, PhCH2), 4.73-4.74 (m, 4H, PhCH2), 4.78-4.82 
(m, 6H, PhCH2), 4.92-4.94 (m, 10H, H-3′′, H-4′′ and PhCH2), 
4.97-5.03 (m, 6H, PhCH2), 5.20 (bs, 2H, H-1′′), 5.36 (bs, 2H, H-
2′) 6.34 (d, 2H, J = 5.0 Hz, H-1′), 7.09-7.34 (m, 90H, Ar-H), 7.75 
(s, 2H, H-5); 
13
C NMR (125 MHz, CDCl3) δ: 64.2, 68.3, 69.1, 
69.15, 69.2, 69.3, 69.39, 69.5, 69.5, 69.6, 69.8, 69.9, 70.4, 70.5, 
70.55, 71.9, 73.3, 73.5, 76.7, 82.8, 95.7, 121.6, 127.6, 127.7, 
127.78, 127.8, 127.9, 128.0, 128.1, 128.3, 128.37, 128.4, 128.5, 
128.55, 128.6, 135.2, 136.1, 136.2, 137.3, 137.5, 138.0; 
31
P 
NMR (202.4 MHz, CDCl3) δ: -1.468, -1.908, -2.138; HRMS (ESI) 
mass calcd for C162H174N6O41P6 [M]
+
 3045.0141, found 
3045.0131. 
d. Protected triazolophostin dimer 15d: 
The reaction of azide 13 (0.2 g, 0.144 mmol) with diyne 14d 
(0.026 g, 0.072 mmol) gave the protected dimer 15d (0.185 g, 
82%) as a colourless gum. 
1
H NMR (500 MHz, CDCl3) δ: 3.53 
(bs, 34H, H-2′′, H-4′′, H-6′′A, and HEG-H), 3.74 (bs, 2H, H-5′′), 
4.23-4.28 (m, 10H, H-5′A and PhCH2), 4.42 (bs, 10H, H-3′, H-4′, 
H-5B′, H-6′′B and PhCH2), 4.56-4.58 (m, 2H, PhCH2), 4.65-4.71 
(m, 10H, PhCH2), 4.83-4.91 (m, 16H, H-3′′, H-4′′ and PhCH2), 
5.11 (bs, 2H, H-1′′), 5.27(bs, 2H, H-2′) 6.24 (d, 2H, J = 5.0 Hz, H-
1′), 6.99-7.24 (m, 90H, Ar-H), 7.62 (s, 2H, H-5); 
13
C NMR (125 
MHz, CDCl3) δ: 64.2, 69.1, 69.16, 69.2, 69.3, 69.4, 69.5, 69.6, 
69.7, 69.8, 69.9, 70.0, 70.4, 70.5, 71.9, 73.3, 73.5, 82.8, 95.7, 
127.5, 127.8, 127.7, 127.75, 127.76, 127.8, 127.9, 128.0, 128.1, 
128.2, 128.3, 128.4, 128.46, 128.49, 128.5, 128.6, 135.2, 136.1, 
137.3, 137.5, 138.0; 
31
P NMR (202.4 MHz, CDCl3) δ: -1.482, -
1.919, -2.168; HRMS (ESI) mass calcd for C166H182N6O43P6 [M]
+
 
3133.0665, found 3133.0669.  
3. General procedure for syntheses of triazolophostin dimers 12a-
d: 
The protected triazolophostin dimers 15a-d (0.15-0.175 g, 
0.05-0.055 mmol) were treated with cyclohexene (3 mL) and 
Pd(OH)2 (20% on carbon, 50 mg) in a mixture of methanol and 
water (9:1 v/v, 10 mL) at 80 °C for 4 h. The reaction mixture 
was then cooled, filtered through a membrane filter, washed 
successively with methanol and water. The combined filtrate 
was evaporated under reduced pressure. The crude product 
thus obtained was purified by ion-exchange column 
chromatography on Q-Sepharose matrix using 0 → 1.0 M TEAB 
as eluent to get pure triazolophostin dimers 12a-d. 
a. Triazolophostin dimer 12a: 
The global debenzylation of 15a (0.15 g, 0.05 mmol) gave 46 
mg (69%) of triazolophostin dimer 12a as a white hygroscopic 
solid: 
1
H NMR (500 MHz, D2O)
 
δ: 3.63-3.65 (m, 8H, DEG-H), 
3.70-3.83 (m, 12H, H-5′A, H-2′′, H-6′′ and DEG-H), 4.09-4.10 (m, 
2H, H-5′′), 4.41 (bs, 2H, H-4′), 4.48 (bs, 2H, H-5′B), 4.62-4.65 (m, 
6H, H-3′, H-3′′ and H-4′′), 5.16 (bs, 2H, H-2′), 5.24 (bs, 2H, H-
1′′), 6.36 (bs, 2H, H-1′), 8.22 (s, 2H, H-5); 
13
C NMR (125 MHz, 
D2O) δ: 60.1, 60.7, 62.8, 68.8, 69.4, 70.5, 71.5, 72.8, 73.7, 76.4, 
77.9, 83.8, 90.9, 97.9, 124.3, 144.1; 
31
P NMR (202.4 MHz, D2O) 
δ: 3.504, 3.583, 4.301; HRMS (ESI) mass calcd for 
C32H58N6O39P6 [M]
+
, 1336.1165, found: 1336.1169.  
b. Triazolophostin dimer 12b: 
The global debenzylation of 15b (0.155 g, 0.051 mmol) gave 51 
mg (72%) of triazolophostin dimer 12b as a white hygroscopic 
solid: 
1
H NMR (500 MHz, D2O)
 
δ: 3.56-3.60 (m, 12H, TEG-H), 
3.69-3.74 (m, 12H, H-5′A, H-2′′, H-6′′ and TEG-H), 4.06 (bs, 2H, 
H-5′′), 4.36 (bs, 2H, H-4′), 4.44 (bs, 2H, H-5′B), 4.50-4.60 (m, 6H, 
H-3′, H-3′′ and H-4′′), 5.12 (bs, 2H, H-2′), 5.18 (bs, 2H, H-1′′), 
6.31 (bs, 2H, H-1′), 8.18 (s, 2H, H-5); 
13
C NMR (125 MHz, D2O) 
δ: 60.1, 60.7, 62.8, 68.8, 69.4, 69.48, 70.4, 71.5, 72.8, 73.7, 
76.4, 77.8, 83.8, 90.8, 97.9, 124.3, 144.1; 
31
P NMR (202.4 MHz, 
D2O) δ: 3.451 (2 x P), 4.224; HRMS (ESI) mass calcd for 
C34H62N6O40P6 [M]
+
, 1380.1427, found: 1380.1420. 
c. Triazolophostin dimer 12c: 
The global debenzylation of 15c (0.16 g, 0.052 mmol) gave 64 
mg (85%) of triazolophostin dimer 12c as a white hygroscopic 
solid: 
1
H NMR (500 MHz, D2O)
 
δ: 3.57-3.61 (m, 16H, TetraEG-
H), 3.69-3.74 (m, 12H, H-5′A, H-2′′, H-6′′ and TetraEG-H), 4.05 
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(bs, 2H, H-5′′), 4.37 (bs, 2H, H-4′), 4.44 (bs, 2H, H-5′B), 4.58-4.61 
(m, 6H, H-3′, H-3′′ and H-4′′), 5.12 (bs, 2H, H-2′), 5.19 (bs, 2H, 
H-1′′), 6.32 (bs, 2H, H-1′), 8.19 (s, 2H, H-5); 
13
C NMR (125 MHz, 
D2O) δ: 60.1, 60.7, 62.9, 68.9, 69.4, 69.5, 70.5, 71.5, 72.8, 73.7, 
76.4, 77.9, 83.8, 90.8, 98.0, 124.3, 144.0; 
31
P NMR (202.4 MHz, 
D2O) δ: 3.478 (2 x P), 4.259; HRMS (ESI) mass calcd for 
C36H66N6O41P6 [M]
+
, 1424.1690, found: 1424.1699. 
d. Triazolophostin dimer 12d: 
The global debenzylation of 15d (0.175 g, 0.055 mmol) gave 65 
mg (77%) of triazolophostin dimer 12d as a white hygroscopic 
solid: 
1
H NMR (500 MHz, D2O)
 
δ: 3.58-3.72 (m, 24H, HEG-H), 
3.77-3.81 (m, 12H, H-5′A, H-2′′, H-6′′ and HEG-H), 4.01 (bs, 2H, 
H-5′′), 4.38-4.48 (m, 4H, H-4′ and H-5′B), 4.58-4.63 (m, 6H, H-3′, 
H-3′′ and H-4′′), 5.12 (bs, 2H, H-2′), 5.20 (bs, 2H, H-1′′), 6.32 
(bs, 2H, H-1′), 8.19 (s, 2H, H-5); 
13
C NMR (125 MHz, D2O) δ: 
60.2, 60.8, 62.9, 68.9, 69.4, 69.5, 70.8, 71.7, 72.6, 73.7, 76.3, 
77.4, 83.8, 90.9, 97.9, 124.2, 144.2; 
31
P NMR (202.4 MHz, D2O) 
δ: 3.482 (2 x P), 4.258; HRMS (ESI) mass calcd for 
C40H74N6O43P6 [M]
+
, 1512.2214, found: 1512.2210. 
 
4. Biological assay: 
Ca
2+
 release from the intracellular stores of saponin-
permeabilized DT40 cells expressing only type 1 IP3Rs was 
measured using a low-affinity Ca
2+
 indicator (Mag-fluo-4) 
trapped within the endoplasmic reticulum as described 
previously.
11
 Briefly, Ca
2+
 uptake was initiated by addition of 
1.5 mM MgATP in cytosol-like medium (140 mM KCl, 20 mM 
NaCl, 1 mM EGTA, 20 mM PIPES, pH 7.0, free [Ca
2+
] ~220 nM 
after addition of ATP) containing p-
trifluoromethoxyphenylhydrazone (FCCP) to inhibit 
mitochondria. After about 120 s, the triazolophostin analogs 
were added with cyclopiazonic acid (10 μM) to inhibit further 
Ca
2+
 uptake. Ca
2+
 release was assessed 10-20 s after addition 
of the analog, and expressed as a fraction of the ATP-
dependent Ca
2+ 
uptake. 
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